N
21.60
-0.69 (-3.10%)
| Previous Close | 22.29 |
| Open | 22.03 |
| Volume | 114,403 |
| Avg. Volume (3M) | 922,160 |
| Market Cap | 2,312,344,832 |
| Price / Sales | 59.79 |
| Price / Book | 5.42 |
| 52 Weeks Range |
| Operating Margin (TTM) | -85.89% |
| Diluted EPS (TTM) | -2.21 |
| Quarterly Revenue Growth (YOY) | 889.80% |
| Total Debt/Equity (MRQ) | 0.13% |
| Current Ratio (MRQ) | 10.61 |
| Operating Cash Flow (TTM) | -154.16 M |
| Levered Free Cash Flow (TTM) | -108.73 M |
| Return on Assets (TTM) | -29.27% |
| Return on Equity (TTM) | -47.37% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | NewAmsterdam Pharma Company N.V | Bearish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.38 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.37% |
| % Held by Institutions | 87.04% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 30 Sep 2024 | 10,473,913 |
| Medicxi Ventures Management (Jersey) Ltd | 31 Dec 2024 | 2,869,565 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 48.00 (HC Wainwright & Co., 122.22%) | Buy |
| Median | 43.50 (101.39%) | |
| Low | 36.00 (Needham, 66.67%) | Buy |
| Average | 42.75 (97.92%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 22.19 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 28 Jan 2025 | 40.00 (85.19%) | Buy | 21.45 |
| 24 Jan 2025 | 40.00 (85.19%) | Buy | 23.60 | |
| HC Wainwright & Co. | 14 Jan 2025 | 48.00 (122.22%) | Buy | 23.67 |
| 30 Dec 2024 | 48.00 (122.22%) | Buy | 25.60 | |
| Scotiabank | 11 Dec 2024 | 47.00 (117.59%) | Buy | 25.57 |
| Needham | 05 Dec 2024 | 36.00 (66.67%) | Buy | 18.07 |
| 21 Nov 2024 | 36.00 (66.67%) | Buy | 20.12 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |